Executive Team


Trenary.jpgRuss Trenary, President & CEO:

Mr. Trenary was chosen to lead InnFocus in 2013. His managerial experience spans over 3 decades and includes specific interfacing in Marketing / Sales / Finance / R&D / Clinical / Regulatory / Manufacturing. He has turned unprofitable $100MM divisions at Allergan (NYSE:AGN) into highly profitable entities, and also significantly increased profitability in $500MM divisions at what is now Abbott-AMO (NYSE:ABT).

Mr. Trenary managed at several levels 4 of the 10 largest first years sales in eye care medical device history at the time of their launch; the first FDA approved foldable IOL implant that shifted the entire industry's paradigm from large incision to phaco assisted small incision cataract surgery ($29MM), second generation foldable IOL implant ($52MM), first laser specifically for hyperopia ($22MM), and the ReZoom™ presbyopia correcting IOL implant ($26MM).

He has been a key instigator in 7 acquisitions including VISX, Inc., ($1.3B), Intralase, Inc., ($800MM), Pharmacia Surgical, ($450MM), Wavefront Sciences, Inc.,($21MM), Ioptex, Inc.,($20MM), Optical Micro Systems, ($16MM), and Orthodontic Design and Production (ODP), for an undisclosed amount.
Among the acquired firms were VISX, Inc., ($1.3B), Intralase, Inc., ($800MM), Pharmacia Surgical, ($450MM), Wavefront Sciences, Inc.,($21MM), Ioptex, Inc.,($20MM), Optical Micro Systems, ($16MM), Orthodontic Design and Production (ODP), for an undisclosed amount.

Mr. Trenary holds an M.B.A. from Michigan State University and B.S. from Miami University (Ohio)



LenPinchuk.jpgLeonard Pinchuk, Ph.D, D.Sc. (h.c.), NAE Co-Founder and Chief Scientific Officer

Dr. Pinchuk is a world-renowned expert in the field of biomaterials and medical devices with over 100 issued U.S. patents including two of the top-five all-time best selling products in cardiovascular therapy; the angioplasty balloon and the drug-eluting coronary stent. He is also the inventor of the company’s materials and products. Dr. Pinchuk received a B.Sc. in chemistry from McGill University in 1976, a Ph.D. Interdisciplinary in engineering, chemistry and medicine from the University of Miami in 1984, an honorary Doctor of Science degree from McGill University in 2005 and was inducted into the National Academy of Engineering in 2012. Dr. Pinchuk began his career at Cordis Corporation in 1983 where he was appointed Manager of its Applied Physics and Chemistry Group. In 1987, he left Cordis to co-found Corvita Corporation with Dr. Normal Weldon, the former CEO of Cordis, where they pioneered the field of stent-grafts. Corvita completed a successful IPO in 1995 and was purchased the following year by Pfizer, Inc. It was merged with Pfizer's Schneider AG division which was purchased by Boston Scientific in 1998. Dr. Pinchuk subsequently founded, with Chief Engineer John B. Martin, Innovia LLC in 2002 which incubated and spun off three successful companies including InnFocus, Inc. in 2004. Dr. Pinchuk ran InnFocus for nine years, raising over $25 million in operating capital.



Yasushi.jpgYasushi P. Kato, Vice President-Research and Development

Dr. Kato provides technical inputs, product and project management expertise for InnFocus projects. He has worked in medical device product development and design for over two decades at various stages of development from concept to market launch in the field of vascular and stent grafts for Corvita Corporation and neurovascular products for J&J Cordis Neurovascular Inc., Fluent in Japanese and Portuguese, during his managerial career  he has acted as a technical liaison to international companies, doctors, and management teams. Dr. Kato holds several U.S. patents, related to medical devices and has several other pending. He has presented, published and reviewed for academic and professional papers and NIH grants in the area of orthopedics, cardiovascular and ophthalmology. He is a member of the Society for Biomaterials and participates in local school-university advisory boards promoting Biomedical Engineering. Dr. Kato holds a Ph.D. in BioMedical Engineering from Rutgers University and a B.S. in Mechanical Engineering from Cornell University.



GuyVanDeWeyer.jpgGuy Van de Weyer Director European, Middle East and African Operations

Mr. Van de Weyer manages the European clinical trial, sales and marketing effort for InnFocus. He graduated as an optometrist and has spent nearly thirty years in the field of ophthalmic surgery and lasers. He assisted in the development and introduction of various innovative surgical techniques, such as phaco-emulsification, laser thermal and conductive keratoplasty, corneal inlays and glaucoma shunt devices. He has given lectures, instructional courses and workshops at multiple universities, surgery centers, international courses and meetings worldwide. His expertise includes the clinical evaluation and introduction of novel innovative surgical instruments, techniques and diagnostic methods to the ophthalmic arena. He has worked with numerous American, European and Japanese manufacturing companies. Born and living in Flanders (Belgium), his operational area covers Europe, Africa and the Middle East. Being fluent in multiple languages and always open for new cultural experiences, he has established life-long relationships around the world.


GuyVanDeWeyer.jpgS. Arieh Zak

Mr. Zak has 25 years of experience in the life science industry. Prior to joining InnFocus, he was Senior Vice President, Regulatory/Clinical/Quality Affairs and General Counsel at PowerVision Inc. in Belmont, California. While at PowerVision, he helped guide the development of the company’s novel, shape-changing accommodating intraocular lens, and directed clinical studies of three generations of the device.  Prior to that, he concurrently held multiple positions at Datascope Corp. including Vice President, Regulatory Affairs (which included responsibility for quality assurance and clinical studies) and Corporate Counsel.  While at Datascope, he was also General Manager of Genisphere Inc., a Datascope subsidiary which developed a proprietary DNA-based nanoparticle technology for use in R&D and medical diagnostics and therapeutic drug delivery. Before entering the life science industry, he practiced law for six years with the international law firm Sullivan & Cromwell.  Mr. Zak holds a Bachelor of Arts degree in Mathematics from Yeshiva University and a J.D. from Columbia Law School..


Website Design By Vivid in Jacksonville, Florida